Related Experiment Videos
Can estradiol modulate schizophrenic symptomatology?
A Riecher-Rössler1, H Häfner, M Stumbaum
1Central Institute of Mental Health, Mannheim, Germany.
Schizophrenia Bulletin
|January 1, 1994
Summary
Estrogen levels, specifically estradiol, may protect against schizophrenia symptoms in women. Lower estradiol levels correlated with increased schizophrenia symptoms, suggesting a potential therapeutic role for estrogens.
Area of Science:
- Neuroendocrinology
- Psychiatry
- Reproductive Biology
Background:
- Epidemiological data suggest estrogens may delay schizophrenia onset in females.
- Animal studies indicate estradiol reduces dopamine (D2) receptor sensitivity.
Purpose of the Study:
- To investigate the antipsychotic properties of estradiol in human females.
- To determine if schizophrenia symptomatology correlates with estradiol serum levels during the menstrual cycle.
Main Methods:
- 32 acutely admitted female schizophrenia patients (ages 18-43) were studied over 3-8 weeks.
- Estradiol serum levels and psychopathology were assessed weekly using rating scales.
- Hormonal parameters and clinical/behavioral assessments were analyzed.
Main Results:
- Estradiol levels were reduced and dampened in patients compared to normal populations.
- A significant association was found between lower estradiol levels and increased psychopathology scores.
- Psychiatric symptoms improved as estradiol levels increased.
Conclusions:
- Findings support a protective role for estrogens in schizophrenia.
- The anti-dopaminergic activity of estrogens may underlie this protective effect.
- Estradiol levels may serve as a biomarker for schizophrenia symptom severity in women.